Narrative updates are currently in beta.

Back to narrative

FDA Clearances And Demographics Will Create Opportunity Despite Valuation Risks

HYPR logo
HYPR
AnalystConsensusTarget
Not Invested
Published 09 Apr 2025

Update shared on15 Aug 2025

Previous
AnalystConsensusTarget's Fair Value
US$1.19
16.5% overvalued intrinsic discount
15 Aug
US$1.39
Loading
1Y
31.1%
7D
19.8%

With both Net Profit Margin and Future P/E essentially unchanged, analysts have maintained their consensus price target for Hyperfine at $1.19.


What's in the News


  • Hyperfine received FDA clearance for its next-generation portable MRI system powered by Optive AI software, delivering significant improvements in image quality, speed, and usability, targeting broader adoption across diverse care settings, including hospitals, neurology offices, and remote environments.
  • Hyperfine commercially launched the next-generation Swoop system and the Optive AI software, making advanced image quality upgrades available to existing and new customers, with initial sales to top-tier hospitals and rollout underway in the U.S., Canada, Australia, and New Zealand.
  • The Swoop system is being actively used in multiple clinical studies: NEURO PMR in neurology offices (successfully enrolled 100 patients), PRIME in emergency departments, and CARE PMR for Alzheimer's patients, demonstrating strong clinician interest and clinical utility across emergency, outpatient, and monitoring settings.
  • Interim data from the CARE PMR study conducted at Washington University showed the Swoop system achieved 100% sensitivity in detecting mild to moderate ARIA-E in Alzheimer's patients on Lecanemab therapy, highlighting its potential for efficient, point-of-care safety monitoring.
  • Hyperfine announced a strategic partnership with NeuroNet Pro to expand awareness and adoption in independent neurology practices, supporting market entry into outpatient neurology and reinforcing the Swoop system's ability to address imaging access barriers in underserved markets.

Valuation Changes


Summary of Valuation Changes for Hyperfine

  • The Consensus Analyst Price Target remained effectively unchanged, at $1.19.
  • The Net Profit Margin for Hyperfine remained effectively unchanged, moving only marginally from 12.46% to 12.49%.
  • The Future P/E for Hyperfine remained effectively unchanged, moving only marginally from 50.11x to 49.97x.

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.